Belén Rubio Viqueira

Phase III, open-label, randomized study to compare CP-675,206 with dacarbazine or temozolomide in patients with advanced melanoma.

Phase II trial of RAD001 in patients with advanced colon carcinoma and mutations in the PI3KCA gene.

Retrospective study to determine phenotype in non-small cell lung cancer, non-squamous cells, in 1st line with Avastin and long progression-free survival.

Phase II study of oral gimatecan (ST1481) as salvage therapy in patients with advanced or metastatic soft tissue sarcoma who have relapsed after an anthracycline/ifosfamide-based chemotherapy regimen.

A dose-finding, open-label, multicenter study to evaluate the safety and tolerability of AMG706, panitumumab, and a combination of AMG 706 + panitumumab when administered with induction chemotherapy (IC) and/or chemoradiotherapy (CRT) in the treatment of subjects with advanced locoregional head and neck squamous cell carcinoma (HNCHC).

Phase I/II trial of erlotinib in combination with gemcitabine, bevacizumab in patients with locally advanced unresectable or metastatic pancreatic adenocarcinoma.

A randomized, multicenter, open-label phase 3 study of chemotherapy with pemetrexed-cisplatin plus IMC-11F8 compared to chemotherapy with pemetrexed-cisplatin alone in the first-line treatment of patients with stage IIIb or IV non-squamous cell lung cancer (NSCLC).

Phase III, randomized, double-blind, placebo-controlled study of oral hydroxamic acid suberoylanilide (L-001079038) in patients with advanced malignant pleural mesothelioma, previously treated with systemic chemotherapy.

A Randomised, Single Blinded, Placebo-controlled, Multi-centre, Phase II Study of Lapatinib in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.

A randomized, multicenter, open-label phase 3 study of gemcitabine-cisplatin plus IMC-11F8 chemotherapy compared to emcitabine-cisplatin alone chemotherapy in the first-line treatment of patients with stage IIIb or IV squamous non-small cell lung cancer (NSCLC).

Phase 3, randomized, double-blind study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer (NSCLC) after disease progression following Platinum-based Prior Therapy.

Phase II study of Pemetrexed compared to the combination of Pemetrexed plus Erlotinib as second-line treatment for non-small cell lung cancer.

A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy of the antigen-specific antitumor immunotherapy recMAGE-A3 + AS15 as adjuvant treatment in patients with resectable MAGEA3-positive non-small cell lung cancer.

Phase II, open-label, multicenter, prospective, randomized study of DTIC or the combination of Gemcitabine and DTIC in advanced soft tissue sarcomas in adults.

Phase III study comparing Pemetrexed, Cisplatin and radiotherapy, followed by consolidation treatment with Pemetrexed, versus Etoposide, Cisplatin and Radiotherapy, followed by consolidation treatment with cytotoxic chemotherapy of choice, in patients with stage III unresectable, locally advanced, predominantly non-squamous non-small cell lung cancer.